Document Type
Article
Publication Date
2-24-2026
Identifier
DOI: 10.1182/bloodadvances.2025016826
Abstract
Ketamine is recommended as an opioid-sparing adjunct for sickle cell disease (SCD)-related pain management. Little is known regarding its use in hospitalized youth with SCD. We aimed to describe trends in ketamine administration and examine associations between ketamine administration and outcomes in hospitalized youth with SCD. We conducted a cross-sectional, multicenter study examining hospital admissions for youth with SCD from 44 children's hospitals in the United States from 2016 to 2023. Youth aged ≥6 months with SCD were identified using International Classification of Diseases tenth revision codes. Exposures included age, sex, race, payor, childhood opportunity index, hydroxyurea administration, and concomitant methadone, buprenorphine, or gabapentinoid administration. The primary outcome was ketamine administration during admission. Secondary outcomes included length of stay, days on IV opioids, all-cause 14-day readmission rates, and intensive care unit stays during admissions with ketamine administered during the first 3 days of hospitalization (early) and hospital day 4 or later (late). From 2016 to 2023, 4.5% (n = 3391) of admissions for patients with SCD included ketamine administration, with prevalence increasing from 2.3% in 2016 to 5.7% in 2023 (P< .001). Age groups ≥12 years and the year ≥2019 was associated with increased odds of ketamine administration. Admissions with ketamine administration were also more likely to have administration of methadone and hydroxyurea. Early vs late ketamine administration was associated with shorter length of stay and fewer parental opioid days, indicating randomized controlled studies are needed to determine not only which patients benefit from ketamine but also the impact of early administration.
Journal Title
Blood Adv
Volume
10
Issue
4
First Page
1106
Last Page
1113
MeSH Keywords
Humans; Anemia, Sickle Cell; Ketamine; Male; Female; Adolescent; Child; Cross-Sectional Studies; Hospitals, Pediatric; Child, Preschool; Infant; Pain Management; Length of Stay; United States; Hospitalization
PubMed ID
41337693
Keywords
Sickle Cell Anemia; Ketamine; Cross-Sectional Studies; Pediatric Hospitals; Pain Management; Length of Stay; United States; Hospitalization
Recommended Citation
Jenkins AM, Hendry E, Power-Hays A, et al. Increasing ketamine administration in children's hospitals for youth with sickle cell disease. Blood Adv. 2026;10(4):1106-1113. doi:10.1182/bloodadvances.2025016826


Comments
This article is available under the Creative Commons CC-BY-NC-ND license and permits non-commercial use of the work as published, without adaptation or alteration provided the work is fully attributed.
Publisher's Link: https://ashpublications.org/bloodadvances/article/10/4/1106/556935/Increasing-ketamine-administration-in-children-s